Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Active not recruiting 3Terminated 2Recruiting 2Completed 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 2Observational 1

Sponsor

Cancer Type

Tumor-Agnostic 1Gynecologic 1Breast 1

Conditions

Breast Neoplasms 11Neoplasm Metastasis 3Uterine Cervical Neoplasms 2Urinary Bladder Neoplasms 2Ovarian Neoplasms 2Multiple Myeloma 2Lymphoma 2Lung Neoplasms 2Hematologic Neoplasms 2Brain Neoplasms 2Uterine Neoplasms 1Urologic Neoplasms 1Thyroid Neoplasms 1Stomach Neoplasms 1Solid Tumors 1Rectal Neoplasms 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Neoplasm, Residual 1Melanoma 1HER2-positive Breast Cancer 1HER2-Positive Primary Breast Cancer 1Glioma 1Esophageal Neoplasms 1Endometrial Neoplasms 1Colorectal Neoplasms 1Colonic Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1

Interventions

pembrolizumab 34Specimen Handling 18Paclitaxel 16Magnetic Resonance Spectroscopy 15Carboplatin 14Biopsy 14Nivolumab 13Ipilimumab 12Gemcitabine 10Irinotecan 9abemaciclib 8Radiosurgery 8atezolizumab 7Radiation 7Pemetrexed 7Cisplatin 7Capecitabine 7130-nm albumin-bound paclitaxel 7trastuzumab deruxtecan 6olaparib 6durvalumab 6avelumab 6Docetaxel 6palbociclib 5osimertinib 5adagrasib 5Trastuzumab 5Fulvestrant 5Cetuximab 5Albumin-Bound Paclitaxel 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Active not recruiting × Neoplasm Metastasis × Ado-Trastuzumab Emtansine × Clear all
NCT06663787 2026-05-13

HER2 CR

Nagoya City University

Active not recruiting
50 enrolled
Breast

Breast Neoplasms, Neoplasm Metastasis, Neoplasm, Residual

NCT05081609 2026-02-24

IL Believe

Ascendis Pharma A/S

Phase 1/2 Active not recruiting
320 enrolled
Gynecologic

Uterine Cervical Neoplasms, Neoplasm Metastasis

NCT00781612 2025-12-24

A Safety Extension Study of Trastuzumab Emtansine in Participants Previously Treated With Trastuzumab Emtansine Alone or in Combination With Other Anti-Cancer Therapy in One of the Parent Studies

Genentech, Inc.

Phase 2 Active not recruiting
720 enrolled
Tumor-Agnostic

Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡